Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, TN 632004, India; Non communicable disease unit, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
Department of Endocrinology, Bharti Hospital, Endocrine Society of India (ESI), Bharti Hospital & B.R.I.D.E, Karnal, India; University Center for Research & Development, Chandigarh University, South Asian Federation of Endocrine Societies (SAFES), India.
Endocrinol Metab Clin North Am. 2023 Sep;52(3):469-484. doi: 10.1016/j.ecl.2023.02.006. Epub 2023 Mar 22.
Metabolic-associated fatty liver disease (MAFLD) is the hepatic manifestation of metabolic syndrome and affects about 55% of people living with diabetes. MAFLD has been shown to be an individual risk factor for cardiovascular disease and its associated mortality. Although common, MAFLD is often underdiagnosed and not given adequate attention during clinical visits. This review highlights the most recent literature available on the evaluation and management of MAFLD in the presence of diabetes. The more recently available antidiabetic agents including glucagon-like peptide-1 analogs and sodium-glucose cotransporter-2 inhibitors have been shown to effectively manage both diabetes and MAFLD.
代谢相关性脂肪性肝病（MAFLD）是代谢综合征的肝脏表现，影响约 55%的糖尿病患者。MAFLD 已被证明是心血管疾病及其相关死亡率的个体危险因素。尽管 MAFLD 很常见，但在临床就诊时往往诊断不足，也没有得到足够的重视。本综述强调了目前关于糖尿病患者 MAFLD 评估和管理的最新文献。最近可用的抗糖尿病药物，包括胰高血糖素样肽-1 类似物和钠-葡萄糖共转运蛋白-2 抑制剂，已被证明可有效治疗糖尿病和 MAFLD。
